18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.